The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENSC | -78.4% | -99.99% | -85.84% | -100% |
| S&P | +13.19% | +87.83% | +13.42% | +142% |
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.49M | -85.6% |
| Market Cap | $7.04M | 111.3% |
| Market Cap / Employee | $0.78M | 0.0% |
| Employees | 9 | 0.0% |
| Net Income | -$3.73M | -663.5% |
| EBITDA | -$3.74M | -680.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.67M | -59.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.36M | -4.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -174.66% | -48.9% |
| Return On Invested Capital | 918.68% | -43.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.99M | -95.0% |
| Operating Free Cash Flow | -$1.87M | -82.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.09 | 0.94 | 1.20 | 1.67 | 247.29% |
| Price to Sales | 2.12 | 0.58 | 0.66 | 1.52 | 183.88% |
| Price to Tangible Book Value | 1.09 | 0.94 | 1.20 | 1.67 | -89.69% |
| Enterprise Value to EBITDA | -2.10 | -0.23 | -1.59 | -1.39 | -48.10% |
| Return on Equity | -471.8% | -200.5% | -253.3% | -270.5% | 43.25% |
| Total Debt | $0.29M | $0.24M | $0.40M | $0.36M | -4.41% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
